JP6795518B2 - キナーゼを阻害する組成物及び方法 - Google Patents
キナーゼを阻害する組成物及び方法 Download PDFInfo
- Publication number
- JP6795518B2 JP6795518B2 JP2017555374A JP2017555374A JP6795518B2 JP 6795518 B2 JP6795518 B2 JP 6795518B2 JP 2017555374 A JP2017555374 A JP 2017555374A JP 2017555374 A JP2017555374 A JP 2017555374A JP 6795518 B2 JP6795518 B2 JP 6795518B2
- Authority
- JP
- Japan
- Prior art keywords
- agents
- virus
- compound
- drugs
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151659P | 2015-04-23 | 2015-04-23 | |
| US62/151,659 | 2015-04-23 | ||
| US201562182955P | 2015-06-22 | 2015-06-22 | |
| US62/182,955 | 2015-06-22 | ||
| PCT/US2016/028914 WO2016172528A1 (en) | 2015-04-23 | 2016-04-22 | Compositions and methods for inhibiting kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513868A JP2018513868A (ja) | 2018-05-31 |
| JP2018513868A5 JP2018513868A5 (enExample) | 2019-05-23 |
| JP6795518B2 true JP6795518B2 (ja) | 2020-12-02 |
Family
ID=57144281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555374A Active JP6795518B2 (ja) | 2015-04-23 | 2016-04-22 | キナーゼを阻害する組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (8) | US9828370B2 (enExample) |
| EP (1) | EP3286179A4 (enExample) |
| JP (1) | JP6795518B2 (enExample) |
| AU (2) | AU2016252860B2 (enExample) |
| CA (1) | CA2980478C (enExample) |
| WO (1) | WO2016172528A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535680A (ja) * | 2016-10-25 | 2019-12-12 | インヒビカーセ セラピューティクス，インコーポレーテッド | キナーゼを阻害する組成物及び方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016252860B2 (en) | 2015-04-23 | 2020-09-17 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
| US10855891B2 (en) | 2016-11-21 | 2020-12-01 | Samsung Electro-Mechanics Co., Ltd. | Apparatus for controlling position of camera module |
| TW202039862A (zh) * | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
| JP2022523562A (ja) * | 2019-03-05 | 2022-04-25 | ホンイー アンド アソシエイツ エルエルシー | 神経変性疾患および癌の治療のための化合物 |
| CN115645393A (zh) * | 2020-02-26 | 2023-01-31 | 上海科技大学 | 二氢杨梅素在抗冠状病毒中的应用 |
| EP4138847A4 (en) * | 2020-04-24 | 2024-05-22 | Memorial Sloan Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
| CN112552283A (zh) * | 2020-12-07 | 2021-03-26 | 天津羲泽润科技有限公司 | 一种新型替尼类药物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1805748B (zh) * | 2003-06-13 | 2010-05-26 | 诺瓦提斯公司 | 作为raf激酶抑制剂的2-氨基嘧啶衍生物 |
| CA2662677C (en) * | 2006-09-05 | 2016-05-31 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| WO2008070350A2 (en) * | 2006-10-27 | 2008-06-12 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
| CN102406648A (zh) | 2010-09-21 | 2012-04-11 | 中国科学院生物物理研究所 | 甲磺酸伊马替尼在制备抗帕金森病药物中的应用 |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| WO2014055938A1 (en) | 2012-10-04 | 2014-04-10 | Inhibikase Therapeutics, Inc. | Novel compounds, their preparation and their uses |
| AU2016252860B2 (en) | 2015-04-23 | 2020-09-17 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
| WO2018081251A1 (en) | 2016-10-25 | 2018-05-03 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
-
2016
- 2016-04-22 AU AU2016252860A patent/AU2016252860B2/en active Active
- 2016-04-22 EP EP16783966.1A patent/EP3286179A4/en active Pending
- 2016-04-22 CA CA2980478A patent/CA2980478C/en active Active
- 2016-04-22 JP JP2017555374A patent/JP6795518B2/ja active Active
- 2016-04-22 US US15/136,497 patent/US9828370B2/en active Active
- 2016-04-22 WO PCT/US2016/028914 patent/WO2016172528A1/en not_active Ceased
-
2017
- 2017-11-07 US US15/805,693 patent/US10118923B2/en active Active
-
2018
- 2018-10-24 US US16/169,683 patent/US10344027B2/en active Active
- 2018-10-24 US US16/169,677 patent/US10316031B2/en active Active
-
2019
- 2019-06-26 US US16/452,828 patent/US10906896B2/en active Active
-
2020
- 2020-12-14 AU AU2020286339A patent/AU2020286339B2/en active Active
-
2021
- 2021-01-05 US US17/141,825 patent/US11407747B2/en active Active
-
2022
- 2022-06-24 US US17/849,141 patent/US11725005B2/en active Active
-
2024
- 2024-09-24 US US18/894,338 patent/US20250250266A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019535680A (ja) * | 2016-10-25 | 2019-12-12 | インヒビカーセ セラピューティクス，インコーポレーテッド | キナーゼを阻害する組成物及び方法 |
| JP7291076B2 (ja) | 2016-10-25 | 2023-06-14 | インヒビカーセ セラピューティクス，インコーポレーテッド | キナーゼを阻害する組成物及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US10316031B2 (en) | 2019-06-11 |
| US10344027B2 (en) | 2019-07-09 |
| AU2020286339A1 (en) | 2021-01-21 |
| US20250250266A1 (en) | 2025-08-07 |
| US20180057488A1 (en) | 2018-03-01 |
| EP3286179A4 (en) | 2018-08-29 |
| US20160311816A1 (en) | 2016-10-27 |
| US10906896B2 (en) | 2021-02-02 |
| EP3286179A1 (en) | 2018-02-28 |
| AU2020286339B2 (en) | 2021-10-21 |
| AU2016252860A1 (en) | 2017-09-21 |
| US20230159514A1 (en) | 2023-05-25 |
| US11407747B2 (en) | 2022-08-09 |
| US9828370B2 (en) | 2017-11-28 |
| US20200031819A1 (en) | 2020-01-30 |
| US20210130343A1 (en) | 2021-05-06 |
| US20190055234A1 (en) | 2019-02-21 |
| WO2016172528A1 (en) | 2016-10-27 |
| AU2016252860B2 (en) | 2020-09-17 |
| CA2980478C (en) | 2024-01-23 |
| JP2018513868A (ja) | 2018-05-31 |
| US20190119266A1 (en) | 2019-04-25 |
| US11725005B2 (en) | 2023-08-15 |
| US10118923B2 (en) | 2018-11-06 |
| CA2980478A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6795518B2 (ja) | キナーゼを阻害する組成物及び方法 | |
| JP6754864B2 (ja) | Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| JP6532878B2 (ja) | 組合せ医薬 | |
| CN103402519B (zh) | 肿瘤治疗剂 | |
| US11248003B2 (en) | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same | |
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| US6809106B1 (en) | Quinoline derivatives as inhibitors of MEK enzymes | |
| JP2021073180A (ja) | 新規な化合物、それらの調製及びそれらの使用 | |
| TWI691500B (zh) | 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物 | |
| JP7291076B2 (ja) | キナーゼを阻害する組成物及び方法 | |
| CN113966329B (zh) | 作为pdl1检查点抑制剂的杂环免疫调节剂 | |
| JP5794873B2 (ja) | 抗腫瘍剤 | |
| TWI343258B (en) | Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190412 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190412 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200423 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201013 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201112 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6795518 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |